The monarcHER study revealed that FHAbe (abemaciclib + fulvestrant + trastuzumab) improved PFS and OS compared with CTH (chemotherapy + trastuzumab) in HR+/HER2+ advanced BC patients who had received at least two previous anti-HER2 treatments (45). This evidence concerns the gene ERBB2 and breast cancer.